Completed PHASE3 INTERVENTIONAL 2-arm NCT02076815

Anagrelide Retard in Essential Thrombocythemia (TEAM-ET)

A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0)

Sponsor: AOP Orphan Pharmaceuticals AG

Conditions Essential Thrombocythemia

Interventions Anagrelide retard Thromboreductin

Updated 6 times since 2017 Last updated: Jul 27, 2015 Started: Feb 28, 2014 Primary completion: Feb 28, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02076815, this PHASE3 trial focuses on Essential Thrombocythemia and remains completed. Sponsored by AOP Orphan Pharmaceuticals AG, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AOP Orphan Pharmaceuticals AG

Data source: AOP Orphan Pharmaceuticals AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bialystok, Poland , Gdansk, Poland , Katowice, Poland , Kaunas, Lithuania , Klaipėda, Lithuania , Linz, Austria , Lublin, Poland , Moscow, Russia , Pleven, Bulgaria , Saint Petersburg, Russia and 7 more locations